Evidence map›Paper›PMID 39045263›Full record

ArticleGynecologic oncology reports2024

Changing the paradigm: Elimination - Not only of cervical cancer.

Jacob Bornstein, Koray Gorkem Sacinti, Mario Preti, Salem Billan, Hosna Razeghian, Colleen K Stockdale

Abstract read
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jacob BornsteinThe Research Institute of Galilee Medical Center, Galilee Medical Center, Nahariya, Israel.
Koray Gorkem SacintiDepartment of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
Mario PretiDepartment of Surgical Sciences, University of Torino, Torino, Italy.
Salem BillanDepartment of Oncology and Radiation, Head and Neck Center, Rambam Health Care Campus, Israel Institute of Technology, Haifa 31096, Israel.
Hosna RazeghianLuigi Vanvitelli University of Campania School of Medicine and Surgery, Naples, Italy.
Colleen K StockdaleDepartment of Obstetrics & Gynecology, University of Iowa, Iowa City, Iowa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The WHO's initiative to eliminate cervical cancer by 2030 does not address the increasing incidence of vulvar, anal, and oropharyngeal cancers linked to high-risk HPV. Currently, the prevention of these three cancers faces various obstacles, such as a lack of specialized screening programs, well-defined management guidelines, and widespread public awareness. Without any interventions, the incidence of these three cancers will likely rise in the upcoming years, increasingly affecting younger individuals. We recommend expanding the WHO's initiative to include vulvar, anal, and oropharyngeal cancers. This involves developing screening and management protocols similar to those for cervical cancer, implementing gender-neutral HPV vaccination programs, establishing clear referral pathways to specialized centers, promoting public awareness, and providing education to healthcare providers and high-risk individuals.

Indexed as

Anal cancerHPVHuman papillomavirusOropharyngeal cancerVulvar cancer

Identifiers

PMID39045263
PMCPMC11263942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.